P/E của cổ phiếu UTHR là bao nhiêu?

United Therapeutics Corporation (UTHR) hiện giao dịch ở mức P/E 20.03 lần.

ROE của cổ phiếu UTHR là bao nhiêu?

United Therapeutics Corporation có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 21.82%.

Tỷ suất cổ tức của UTHR là bao nhiêu?

United Therapeutics Corporation có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của UTHR là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của UTHR ở mức 85/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu UTHR không?

Điểm AI Timing của UTHR là 26/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu UTHR thuộc ngành nào?

United Therapeutics Corporation được xếp vào ngành Healthcare >> Drug Manufacturers - Specialty & Generic trên sàn NASDAQ

Cổ phiếu UTHR (NASDAQ) | UNITED THERAPEUTICS CORPORATION

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

UTHR AI Analysis Summary

Our AI summary for UTHR: United Therapeutics Corporation (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 20.03, ROE of 21.82%, a dividend yield of 0.00%. Its financial Quality Score stands at 85/100 — fundamentals stronger than most of the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

UTHR

United Therapeutics Corporation

USD 516.31

-1.40 (-0.27%) Day Change

Watchlist Portfolio Compare Chart

20.03

P/E

0.14

D/E

21.8%

ROE

19.2%

ROA

0.00%

Div Yield

0.86

PEG

UNITED THERAPEUTICS CORPORATION
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 516.31 Price -1.40 (-0.27%) Day Change	NEWS SCORE: 99

UTHR Chất lượng tổng thể của cố phiếu Rất tốt ( Chất lượng = 85) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

85 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: [-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

57%

In Recommendations?	In "Invest - GOOD" Section
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	99
Magic Formula Rank by ROA	647
Magic Formula Rank by ROE	647
Magic Formula Rank by ROIC	690
Price	516.31
PBV / Sector	4.37 / 9.54
Earning Per Share	25.78

PE / Sector	20.03 / 28.71
PEG or PE/Growth / Sector	0.86 / -0.10
Average 1M Daily Value	192.66 M GREAT
Average 1W Daily Value	197.99 M GREAT

Yếu tố Kỹ thuật

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

58%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	40.61 / 15.25 GREAT
NPM Average (%) / Sector	40.79 / -10.83 GREAT
NPM Change Average (%) / Sector	2.16 / 117.82
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	19.17 / 8.18 GOOD
ROA Average (%) / Sector	15.62 / 2.87 GOOD
ROA Change Average (%) / Sector	12.47 / 113.04 GOOD
ROE (%) / Sector	21.82 / 26.68 GOOD
ROE Average (%) / Sector	18.16 / 13.89
ROE Change Average (%) / Sector	9.66 / 379.20
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.52
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.83

Chi tiết đăng ký

Analyze Date	2026-08-04 08:02:19
Symbol	UTHR
Name	UNITED THERAPEUTICS CORPORATION
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	49.80 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	25,783.06 / 10,605.93

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1000 Spring Street, Silver Spring, MD, United States, 20910

Phone: 301 608 9292

Website: https://www.unither.com

Employees: 1,400

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.